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Abstract: 
Introduction: Oral anticoagulation with warfarin is the accepted technique for treatment and prophylaxis of thromboembolic 
diseases. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most broadly administered medications to control 
musculoskeletal pain or inflammation. besides to their antiplatelet work, NSAIDs can influence the pharmacologic activity of 
warfarin through their immediate interaction. High protein binding and the cytochrome P450 (CYP)- dependent clearance 
systems of NSAIDs can influence the serum levels of warfarin. 
Aim of work: In this review, we will discuss whether using warfarin with NSAID has any effect on the pharmacokinetics and 
pharmacodynamics of both drugs. 
Methodology: We conducted this review using a comprehensive search of MEDLINE, PubMed, and EMBASE, January 1985, 
through February 2017. The following search terms were used: Non-steroidal anti-inflammatory drug mechanism, warfarin 
mechanism, adverse effects of NSAID, adverse effect of warfarin, NSAID-warfarin interaction 
 
Conclusions: Co-administration of NSAIDs and Warfarin is a topic of debate. However, there are reasons for concern. Some 
NSAIDs alter hemostasis and, when combined with warfarin, may lead to an increase in bleeding time. There is also a risk of 
increased hepatic and renal toxicity which complicates things further. Balancing the pros and cons of this drug combination 
should be carefully done on a case to case basis to avoid any negative consequences.  
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INTRODUCTION: 
Oral anticoagulation with warfarin is the accepted 
technique for treatment and prophylaxis of 
thromboembolic diseases. While the adequacy of 
warfarin on anticoagulation is well known, it can 
cause a conceivably lethal complication, hemorrhage. 
Hemorrhage appear almost as much as 9.6% of 
patients every year, including a deadly case rate of 
0.6% [1].  
Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
the most broadly administered medications to control 
musculoskeletal pain or inflammation. Besides to 
their antiplatelet work, NSAIDs can influence the 
pharmacologic activity of warfarin through their 
immediate interaction. High protein binding and the 
cytochrome P450 (CYP)- dependent clearance 
systems of NSAIDs can influence the serum levels of 
warfarin. Therefore, there have been many case 
reports depicting bleeding complications after 
NSAIDs were given alongside warfarin [2].  
The level of anticoagulation with warfarin is typically 
checked with international normalized ratio (INR), 
which is a solid indicator of future bleeding risk; 
every one-point elevation in INR builds bleeding risk 
by 54.0%. Hence, checking INR is essential when 
prescribing warfarin. In this regard, stopping 
NSAIDs or changing warfarin dose ought to be 
considered if INR increases after adding NSAID [3].  
METHODOLOGY: 
• Data Sources and Search terms 
We conducted this review using a comprehensive 
search of MEDLINE, PubMed, and EMBASE, 
January 1985, through February 2017. The following 
search terms were used: 
 
• Data Extraction 
Two reviewers have independently reviewed the 
studies, abstracted data, and disagreements were 
resolved by consensus. Studies were evaluated for 
quality and a review protocol was followed 
throughout. 
The study was approved by the ethical board of King 
Abdulaziz University Hospital 
NON-STEROIDAL ANTI-INFLAMMATORY 
DRUGS (NSAIDS): 
Mechanism of Action 
The significant therapeutic actions of NSAIDs are 
fundamentally enacted by their capacity to block 
certain prostaglandins (PGs) synthesis through the 
cyclooxygenase enzymes (COX-1 and COX-2) 
inhibition. COX-1 produces prostaglandins and 
thromboxane A2 which control mucosal barrier in 
GI-tract, renal homeostasis, platelet aggregation and 
other physiological functions. COX-2 produces PGs 
that related to inflammation, pain and fever. COX-1 
is expressed in normal cells, while COX-2 is induced 
in inflammatory cells. COX-2 inhibition no definitely 
represents the desired effect of NSAIDs' anti-
inflammatory, antipyretic and analgesic reaction; 
while COX-1 inhibition plays a great role in the 
complications such as GI and renal toxicities [2].  
Most NSAIDs are readily absorbed in the 
gastrointestinal system and have high bioavailability. 
A few medications, for example, diclofenac undergo 
hepatic first-pass metabolism which led to a decrease 
in bioavailability. While other medications such as 
sulindac and parecoxib are prodrugs and need hepatic 
metabolism to become their active metabolites 
(sulindac sulfide and valdecoxib, respectively). 
NSAIDs are profoundly bound to plasma proteins. 
NSAIDs are typically metabolized in the liver and 
excreted through the kidney. Commonly 
administered NSAIDs medications have a variable 
half-life; they can be around the range of 0.25-0.3 
hours such as aspirin or 45-50 hours such as 
piroxicam. All these pharmacokinetics parameters 
can be altered with age since the elderly have low 
body water compared to adults. Protein binding 
might be diminished, and volumes of distribution 
might be changed [4].  
Gastrointestinal Adverse Effects 
The injury of gastric and duodenal mucosa caused by 
NSAIDs has been significantly evaluated. These 
upper GI reactions include bothersome 
manifestations with or without mucosal damage, 
asymptomatic mucosal lesions, and drastic 
complications, including death.  
Around 30 to 50% of NSAID consumers have 
endoscopic lesions, (such as subepithelial 
hemorrhages, erosions, and ulcerations), majorly 
situated in gastric antrum, and frequently without 
clinical appearances. commonly, these lesions have 
no clinical importance and lessen or even vanish with 
prolonged use, most likely due to the adaptation of 
mucosal layer to aggression. In contrast, up to 40% of 
NSAIDs consumers have upper GI side effects, 
commonly being gastroesophageal reflux 
(regurgitation and/or heartburn) and dyspeptic 
manifestations (includes belching, epigastric 
discomfort, bloating, early satiety and postprandial 
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nausea) [5]. The beginning of these side effects 
appears to fluctuate depending upon the type of 
NSAID. A meta-analysis of the available trials from 
the Cochrane collaboration presumed that COX-2 
selective inhibitor (celecoxib) was related with less 
symptomatic ulcers, endoscopically identified ulcers 
and cessations for GI adverse events compared with 
ns-NSAIDs (naproxen, diclofenac, ibuprofen and 
loxoprofen). regrettably, these side effects are not 
predictive of the presence of mucosal damage. 
Roughly 50% of individuals with side effects have no 
mucosal lesions; however, >50% of consumers with 
drastic peptic ulcer complications had no previous 
warning manifestations [6].  
The most critical upper GI complications are the 
event of symptomatic and/or complicated peptic 
ulcer. NSAID-related upper GI side effects include 
bleeding, perforation and obstruction. Around 1 to 
2% of NSAID consumers encountered a drastic 
complication amid treatment. Case-control trials and 
a meta-analysis have demonstrated that the average 
relative risk (RR) of creating uncomplicated or 
complicated peptic ulcer is fourfold and fivefold in 
NSAIDs consumers compared with non-consumers. 
The risk is recommended to be higher amid the first 
month of treatment (RR, 5.7; 95% confidence 
interval CI, 4.9 to 6.6), but stays raised amid 
administration and 2 months after stopping treatment 
[7]. 
WARFARIN: 
Mechanism of Action 
Warfarin's anticoagulant effects help halt clot 
development and the extension of any existing clots, 
yet it has no immediate impact on clot removal or 
reversing ischemic tissue injury. Warfarin shows its 
anticoagulation effects through the intrinsic and 
extrinsic pathways in the clotting cascade. This 
happens by inhibiting the synthesis of vitamin K-
dependent clotting factors (II, VII, IX, and X) and the 
anticoagulant proteins C and S. Warfarin meddles 
with the synthesis of clotting factors by inhibiting the 
vitamin K oxidation-reduction cycle required for the 
carboxylation of clotting factors. This finally reduces 
the amount of active vitamin K reserves available to 
act as a cofactor in the development of glutamic acid 
residues inside the previously mentioned clotting 
factors [8].  
Warfarin's hepatic metabolism and protein binding 
are the most widely recognized mechanisms for the 
event of drug-drug interactions. Warfarin is 
metabolized through cytochrome P450 system by 
2C9, 1A2, and 3A4. It is a racemic mixture of R and 
S enantiomers with the S-enantiomer being 2.7 to 3.8 
times more intense than the R-enantiomer. Since the 
S enantiomer is more powerful and is principally 
used by CYP 2C9, drug-drug interactions effecting 
this pathway might be more remarkable. Drugs with a 
higher protein binding affinity than warfarin (e.g., 
aspirin) can displace warfarin creating further free 
warfarin inside the blood stream [9].  
Adverse Effects 
Clinical manifestations of bleeding should be 
monitored upon initial administration of warfarin 
since this is the most common risk factor. infrequent 
yet serious adverse effects include tissue necrosis, 
calciphylaxis, and systemic atheroemboli and 
cholesterol microemboli. Tissue necrosis typically 
starts within days of initiating warfarin and has been 
related with individuals having deficiencies of 
proteins C or S. Warfarin lessens the synthesis of 
both of these normally occurring anticoagulant 
proteins. combined administration of heparin for 5 to 
7 days may limit the frequency of necrosis when 
starting warfarin. Calciphylaxis was recently added 
as a warning to warfarin and can result in 
calciphylaxis or calcium uremic arteriolopathy in 
patients with or without end-stage renal disease. 
systemic atheroemboli and cholesterol microemboli 
may occur because of the release of plaque emboli 
after the administration of warfarin. Different areas 
inside the body can be influenced including the feet. 
In particular, purple toe syndrome happens when 
microemboli travel to a patient's toes and may happen 
months after the initiation of warfarin. In the 
instances of all drastic adverse effects, alternative 
anticoagulation treatment ought to be considered 
unless the risk exceeds the advantage of taking an 
anticoagulant [10;11].  
There are several drugs and herbal products that can 
potentiate or repress the effects of warfarin. Any drug 
that influences the capacity to clot, for instance, other 
anticoagulants, antiplatelets, nonsteroidal anti-
inflammatory agents (NSAIDs), and selective 
serotonin reuptake inhibitors (SSRIs) will expand the 
risk of bleeding even when there is not a specific 
drug-drug interaction. Drug-drug interactions are 
various and more often lead to an elevation in 
PT/INR levels except if the associative medicine is a 
CYP P450 inducer such as rifampin [12].  
Concomitant use of Warfarin and NSAIDs 
As a class, NSAIDs are not inclined to a direct 
pharmacodynamic interaction with anticoagulants, 
such as warfarin; nevertheless, simultaneous 
administration of NSAIDs and anti-thrombotics may 
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additionally enhance the probability of GI 
bleeding.82 A Danish cohort study (N=4,204) found 
that anticoagulants alone elevate the risk of GI 
bleeding (standardized incidence ratio [SIR]: 4.0; 
95% CI: 2.8– 5.6), and risk was additionally elevated 
by combined use of acetaminophen (SIR: 4.4; 95% 
CI: 1.2– 11.4) or non-aspirin NSAIDs (SIR: 8.0; 95% 
CI: 2.1– 20.4; no specific NSAIDs or doses reported) 
[13]. Metabolism of S-warfarin, the most clinically 
important warfarin isomer, happens by means of 
CYP2C9. Ibuprofen and different NSAIDs are also 
substrates of CYP2C985 and may in this manner 
elevate anticoagulant action by postponing S-
warfarin metabolism. Therefore, it might be 
reasonable to evade prescription -strength NSAIDs in 
patients consuming warfarin. Conversely, one of the 
metabolites of acetaminophen (N-acetyl-para-
benzoquinone-imine) interferes with enzymes 
involved with the vitamin K cycle, which eventually 
can prompt decrease in synthesis of clotting factors 
and excessive anticoagulation [14]. Even with short-
term use, acetaminophen given simultaneously with 
anticoagulants may elevate international normalized 
ratio (INR), suggesting an increase in bleeding risk 
and requiring close INR monitoring and possible 
warfarin dosage adjustments [15].  
Additionally, to having direct effects on warfarin, 
NSAIDs potentially increase the side effects of 
anticoagulants administered orally by two other 
mechanisms. ASA is known to influence primary 
hemostasis in some typical individuals by causing 
irreversible acetylation of cyclo-oxygenase in 
platelets, which results in a prolongation of the 
bleeding time. Alternate NSAIDs additionally 
influence platelet function yet generally in a 
reversible fashion, and their effects on bleeding time 
and bleeding tendency are less pronounced. In doses 
well over the therapeutic range ASA could also have 
a hypoprothrombonemic effect by diminishing the 
vitamin K-dependent clotting factors,' yet. this is 
rarely an issue in clinical practice [14].  
It is also conceivable that the severity of 
gastrointestinal bleeding induced by ASA or other 
NSAIDs could be elevated by the combined use of 
anticoagulants. The role NSAIDs play in inducing 
acute upper gastrointestinal tract hemorrhage is as yet 
debatable, however the risk from normal ASA use 
has been estimated at no more than 15 episodes per 
100 000 consumers for every year. The use of alcohol 
in individuals taking warfarin might be a more 
serious issue than this. One of the few studies to 
observe the complications of combined ASA and 
warfarin treatment found that the rate of 
gastrointestinal bleeding was increased over that seen 
with warfarin alone. However, there was a high 
correlation among the prothrombin index and the 
frequency of bleeding, and the prothrombin index 
was quite often over the therapeutic levels. Almost all 
the episodes of gastrointestinal bleeding happened 
amid the first month of combined therapy [16].  
 
There are two different purposes for caution. First, 
individual differences regarding these medications 
and their interactions do happen. ASA's ability to 
delay the bleeding time ranges from none in a few 
people to marked in others and has additionally been 
appeared to be dose and age-dependent. Second, 
patients taking warfarin and NSAIDs in combination 
may as well have renal or liver dysfunction or be 
taking still different other medications. Most trials on 
NSAID/warfarin interaction have included healthy 
volunteers. The potential for more complex 
interactions is therefore extraordinary [17].  
Mechanisms of Adverse Drug Interactions 
Direct Hypo-prothrombinemic Effect of Aspirin 
Aspirin and different other salicylates may have a 
hypo-prothrombinemic effect by depressing the 
vitamin K-dependent synthesis of clotting factors Vll, 
IX, and X. nevertheless, such an activity just winds 
up critical if the equivalent exceeds 6 g (for a 70-kg 
man) of aspirin every day has been ingested." The PT 
is rarely prolonged except if the serum salicylate 
concentrations exceed of 300 mg/ml.," concentrations 
at which salicylate toxicity is more certainly [18].  
Pharmacokinetic Mechanisms  
Two main types of pharmacokinetic interactions have 
been reported: displacement of warfarin from plasma 
albumin and blockade of the metabolism of warfarin 
by NSAIDs. The role of protein binding displacement 
in interactions with warfarin has been 
overemphasized. Although most NSAIDs, which are 
extremely protein-bound, have been found to displace 
warfarin from plasma albumin binding zones in vitro, 
this interaction has only been shown in vivo with 
some NSAIDs [19].  
Additionally, in vivo trials have demonstrated that 
this displacement does not importantly elevate the 
anticoagulant activity of warfarin. An elevation in the 
plasma concentration of unbound (pharmacologically 
active) warfarin following the administration of the 
displacing NSAlD will be transient due to combining 
increase in the clearance of unbound warfarin until 
the previous concentration is hit. Therefore, 
displacement might be vital only for intermittent 
warfarin administration and on introduction and 
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withdrawal of the displacing NSAIDs. In such 
circumstances, the effect again is transient and 
steady-state ought to be reached after 7-10 days. A 
clinically important interaction also might be more 
likely in the presence of high concentrations of 
NSAIDs in individuals with slow elimination of 
warfarin (e.g., those with severe heart failure or 
impaired liver function) [20].  
Phenylbutazone considerably inhibits the metabolism 
of S-warfarin while elevating the hepatic clearance of 
R-warfarin." The net outcome is increased 
anticoagulation without an adjustment in the overall 
clearance of racemic warfarin. It is likely that analogs 
of phenylbutazone (oxyphenbutazone, apazone, and 
sulfinpyrazone) will interact with warfarin in a 
similar manner. Same data for other NSAlDs are not 
available, as plasma concentrations of total warfarin 
as opposed to its isomers have been estimated in 
studies of interaction with warfarin [21].  
Pharmacodynamic Mechanisms  
Two pharmacodynamic interactions have been 
reported: direct effects on platelets and producing 
upper gastrointestinal (GI) bleeding. Aspirin 
irreversibly acetylates platelet cyclooxygenase at low 
or high dosages and produces irreversible 
consequences for platelet function that persevere for 
the life of the aspirin-treated treated platelet." Platelet 
aggregation furthermore might be inhibited and the 
bleeding time delayed. Similarly, however usually 
lesser, consequences for platelet function might be 
seen with non-aspirin NSAIDs, yet unlike aspirin, 
these effects are lost when the medication or any 
active metabolites are removed from the circulation.' 
Therefore, the effects are typically reversible in 24 
hours for short-acting NSAlDs, yet may proceed for 
many days longer-acting NSAIDS. Because of the 
side effects on hemostasis, NSAlDs increase the risk 
of bleeding from the GI tract or different other 
locations amid combined use [20].  
Several studies have demonstrated that an individual 
exposed to NSAIDs has 3-4 times the risk of upper 
GI bleeding, perforation, or both than an individual 
who has not been exposed." An extensive variety of 
mechanisms could clarify the occurrence of NSAlD-
induced gastroduodenal mucosal injury, including the 
inhibition of bicarbonate secretion, effects on mucus 
development, and vascular actions. The individual 
risks are low, of the order of 1 episode for each 
10,000 NSAID prescriptions issued to individuals 
aged 60 years and older in the UK. Due to numerous 
such prescriptions are issued, there are numerous 
episodes. In a study of patients with rheumatoid 
arthritis, the rate of hospitalization due to upper 01 
bleeding in individuals taking NSAIDs was 1.58% 
every year compared with 0,3% in those not taking 
the agents." In addition to old age, other clinical 
variables of predictive value included use of 
prednisone, disability, the dose of NSAIDs, and past 
problems with NSAIDs. Upper GI bleeding is 
expected to be more notable in individuals taking 
warfarin [7].  
CONCLUSION: 
Co-administration of NSAIDs and Warfarin is a topic 
of debate. However, there are reasons for concern. 
Some NSAIDs alter hemostasis and, when combined 
with warfarin, may lead to an increase in bleeding 
time. Upper GI bleeding can occur in patients taking 
NSAIDs which is further complicated when warfarin 
is added to the mix. There is also a risk of increased 
hepatic and renal toxicity which complicates things 
further. Balancing the pros and cons of this drug 
combination should be carefully done on a case to 
case basis to avoid any negative consequences. More 
studies should be conducted to clarify the 
implications of combining NSAIDs and warfarin. 
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